title: Cost-effectiveness of thrombolytic therapy for acute myocardial infarction.
abstract: OBJECTIVE
  To estimate the cost-effectiveness of thrombolytic therapy versus no thrombolytic therapy for patients following acute myocardial infarction, focusing on the impact of time to treatment on outcome.
  
  
  METHODS
  A decision model was developed to assess the benefits, risks, and costs associated with thrombolytic therapy for treatment of acute myocardial infarction compared with standard nonthrombolytic therapy. The model used pooled data from a recent study of nine large randomized, controlled clinical trials and 12-month outcome data from a recently published meta-analysis of thrombolytic therapy trial data. Outcomes were expressed in terms of survival to hospital discharge and survival to 1 year after discharge. The risks of treatment that led to death, morbidity, or added costs were estimated. The model determined excess and marginal costs per death averted to hospital discharge and at 1 year. Results were also estimated in terms of cost per year of life saved. Sensitivity analyses included variations in time to treatment and drug cost.
  
  
  RESULTS
  The marginal cost of thrombolytic therapy per death averted at 1 year was $222,344, or $14,438 per year of life saved. For patients treated within 6 hours of acute myocardial infarction, the marginal cost per death averted was $181,536 at 1 year, or $11,788 per year of life saved.
  
  
  CONCLUSIONS
  Thrombolytic therapy is significantly more cost-effective than many other cardiovascular interventions and compares favorably with other forms of medical therapy. Results suggest that shortening the time to treatment has a critical impact on the cost-effectiveness of thrombolytic therapy.
authors.affiliation: Battelle Centers for Public Health Research and Evaluation, Arlington, VA, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Castillo
authors.forename: C S
authors.initials: CS
authors.lastname: Palmer
authors.forename: M T
authors.initials: MT
authors.lastname: Halpern
authors.forename: E J
authors.initials: EJ
authors.lastname: Hatziandreu
authors.forename: B J
authors.initials: BJ
authors.lastname: Gersh
mesh_terms: D000208:Acute Disease; D000368:Aged; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000191:economics* / Q000523:psychology / Q000628:therapy*; D011788:Quality of Life; D012008:Recurrence; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000191:economics*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents